All News

Dougados et al. MACE in tofa clinical programme. Baseline CV risk important. Overall MACE IR 0.38 [0.26-0.54]. MACE IR lower than in ORAL Surveillance in CV enriched pop 0.72 [0.46-1.09]. @RheumNow #EULAR2022 OP0264 https://t.co/lGTTEx0X5p https://t.co/MvD6kjkpse

EULAR Abstract Archive

#EULAR2022 POS0210 RNA sequencing in 11 RA-ILD patients vs 9 RA pts ⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions @RheumNow @fahidalghanim https://t.co/FIrZfzZV1C

TNFi were going to unleash a TB wave What has the biologic era really done for TB & opportunistic infx? Hospitalised data from Western Australia post-2003: TB actually not up (screening) myocoses were up (no screening) Dare I say it: screening works OP0274 #EULAR2022 @RheumNow

#EULAR2022 – Day 2 Report A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, and fibromyalgia. https://t.co/dpq5Het2rN https://t.co/NIfkjhHw86

https://bit.ly/3x75CxY

#EULAR2022 POS0256 by @CaoilfhionnMD, @DrLisaCS, @JuliePaikMD from @HopkinsRheum 10% of pts seronegative for COVID antibodies after vaccination ⭐️Risk factors: Non-white, J&J vaccine, MMF, RTX, GC, combination Rx, not-withholding peri-vaccination immunosuppression @Rheumnow https://t.co/Izd4QJlOWH

OP0280 WIN-lupus study eval if #SLE LN pts in remission can stop Rx. In pts who continued vs. stopped Rx: renal relapse 12% vs. 27%, p=0.08 and severe SLE flare 12 vs 32%, p=0.03; pts relapsing had inc baseline UPCR/SLEDAI score; +APS; lower lymphs/C3 . #EULAR2022 @rheumnow

Torgashina et al Rituximab in Sjogrens ILD. ILD first manifestation of Sjogrens in 26%. Rituximab improvement in 37% and stabilisation in 47%. @RheumNow #EULAR2022 POS0710 https://t.co/CCnPVrTGfI

#EULAR2022 OP0278: Increase in risk of CVA compared to general population ~1.2x risk ⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era ⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop @Rheumnow https://t.co/r8QsJABfvx

Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI

Pan et al. SPI-62 (11beta-hydroxysteroid dehydrogenase inhibitor) minimises steroid side effects in animal studies. Now going on to a clinical trial in PMR. Exciting as steroid adverse events are a huge problem in PMR/GCA @RheumNow #EULAR2022 POS1332 https://t.co/NEoIx971jS

Can we predict VTEs from JAKi for RA at all? Baseline elevated D-dimer pts who go on to develop VTE (but not baseline CRP, so not just general inflamm) Questions raised about effect modification for VTE following JAKi too. This story not yet done OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl

#EULAR2022 OP0277 MSK IRAE from Checkpoint inhibitors ⭐️118 pts w MSK complaints 76% w arthralgias/myalgias, 30% with inflammatory rheumatic features Most grade 1/2, 2 grade 4 (myositis) 23 (19.5%) required d/c, time of resolution ~3 mos, 20% persistence at end of study @RheumNow https://t.co/SINqmmjsLq

Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M

Tomelleri @tomelleri_a et al. GCA. Tocilizumab weekly x 1 year, then every other week x 1 year, then stop. 2 PMR flares during toc. 1 month post-stop 100% remission. 6 months post-stop 24% GCA flare! Some patients seem to need indefinite toc @RheumNow #EULAR2022 POS0266 https://t.co/8I5GQ08HDr

Long-term low-dose steroids for RA: can it be weaned? Weaning after 2y of blinded add-on in RA: either PNL 5mg/d or placebo No substantial evidence of adrenal insufficiency - symptoms same - cortisol/ACTH same It's never too late to wean the pred! OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb

🧫 JAKi and NK cells activation: JAKi and particularly TOFA impacts NK cells: *phenotype *function *impairs the control of proliferation of lung cancer and lymphoma cell lines An explanation for the increase of cancer events in ORAL surveillance? @RheumNow #EULAR2022 OP0265 https://t.co/LzMLdzcsDU

MACE events no diff in German RA Rabbit registry of only humans shows #baricitinib and #tofacitinib vs #TNFis @RheumNow @eular_org #EULAR2022 OP0135 https://t.co/O8iOA7jpal

Aurelie Najm on Twitter: "RABBIT registry and MACE in RA
No difference…

#EULAR2022 OP0274 Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease: ⭐️9% with RA, 6% with PsA and AS in Western Australia ⭐️Decrease overall since 1985, but recent increase ⭐️Sharp rise of mycotic infections ⭐️No PJP, likely due to ppx @Rheumnow

Low socioeconomic status should on the list as a high risk factor (#notJUSTrace) https://t.co/zikGGLISSN

EnvisionRheumat on Twitter: "#EULAR2022 
How to Manage (HOT): Lupus Ne…

Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE

Topics

All News

Do you get our email newsletter?